Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia-Reference-Cited by-同舟云学术

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

Published:2010-07 Issue:7 Volume:34 Page:877-882
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Karp Judith E.,Blackford Amanda,Smith B. Douglas,Alino Katrina,Seung Amy Hatfield,Bolaños-Meade Javier,Greer Jacqueline M.,Carraway Hetty E.,Gore Steven D.,Jones Richard J.,Levis Mark J.,McDevitt Michael A.,Doyle L. Austin,Wright John J.

Funder

National Cancer Institute (NCI) Cooperative Agreement

NCI Cancer Center

National Center for Research Resources

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference35 articles.

1. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461);Byrd;Blood,2002

2. Acute myeloid leukemia and myelodysplastic syndromes in older patients;Estey;J Clin Oncol,2007

3. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia;Schlenk;N Engl J Med,2008